Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Pharmaceuticals News
US Supreme Court backs generic drugmaker in 'skinny label' patent case
* Case involved Amarin's cardiovascular drug Vascepa
Hikma Pharmaceuticals
Abivax
US Supreme Court backs generic drugmaker in 'skinny label' patent case
* Case involved Amarin's cardiovascular drug Vascepa
Incanthera names new CEO, secures funding to buy Swiss skincare brand
(Alliance News) - Incanthera PLC on Thursday appointed a new chief executive, who will provide the company with funding to support a new acquisition.
Immupharma
EARNINGS AND TRADING: CRISM wins "highly competitive" UK grant
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately report...
FinsetaIncreased investment sees Ondine Biomedical post widened annual loss
(Alliance News) - Ondine Biomedical Inc on Thursday said higher investment, which is designed to support future growth, impacted margins in 2025.
Ondine Biomed'It's still working': More are living with cancer as era of targeted drugs takes hold
* Targeted therapies drive rising cancer survival rates, experts say
Revolution Medicines IncAstraZeneca breast cancer drug camizestrant shows "sustained" benefit
(Alliance News) - AstraZeneca PLC on Tuesday reported encouraging test results for its breast cancer treatment camizestrant.
AstrazenecaTRADING: Medpal dispenses record number of prescription items in May
(Alliance News) - The following is a round-up of trading updates by London-listed companies, issued on Monday and not separately reported by Alliance ...
AmcomriModerna and other groups get $60 million to develop Ebola vaccine
* CEPI commits just over $60 million to three vaccine groups
ModernaTRADING UPDATES: Novacyt plans job cuts; EnSilica's contract win
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:
CheckitAstraZeneca hails Imfinzi and Imjudo liver cancer trial results
(Alliance News) - AstraZeneca PLC on Monday posted positive phase-three trial results for a combination of its drugs Imfinzi and Imjudo to treat a for...
EARNINGS AND TRADING: Petra cost cuts, business rescue at Finsch mine
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported...
Petra DiamondsAstraZeneca highlights data insights from Cares clinical programme
(Alliance News) - AstraZeneca PLC on Friday announced that the CARES phase 3 clinical programme did not meet a primary endpoint, but noted insightful ...
CelLBxHealth shares jump on partnership with AstraZeneca
(Alliance News) - CelLBxHealth PLC on Friday disclosed that it has entered a partnership with AstraZeneca PLC.
CellbxhealthEARNINGS & TRADING: Microsalt lowers sales 2026 guidance
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately repor...
MicrosaltIN BRIEF: Nuformix interim loss narrows; aims to raise value of assets
Nuformix PLC - London-based developer of treatments for fibrosis and oncology - Pretax loss narrows to GBP346,577 in the six months ended March 31, fr...
NuformixGSK hails "major step forward" after "positive" hepatitis drug results
(Alliance News) - GSK PLC on Thursday reported "positive" phase 3 trial data for its hepatitis B treatment, Bepirovirsen, which it said could "redefin...
GlaxosmithklineGSK's chronic hepatitis B drug helps one in five achieve functional cure in key studies
* GSK's drug helps 19% of patients achieve functional cure across two studies
IN BRIEF: ValiRx subsidiary Cytolytix granted "core" European patent
ValiRx PLC - London-based life science company - Majority-owned subsidiary Cytolytix Ltd has its European patent "Nanoparticle for Anti-Cancer Peptide...
ValiRx
Follow the stocks
